COMMUNIQUÉS West-GlobeNewswire

Palvella Therapeutics to Host Full Year 2024 Financial Results Conference Call on March 31, 2025
18/03/2025
WAYNE, Pa., March 18, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat [...]
March 2025 Letter to Shareholders
18/03/2025
VANCOUVER, Washington, March 18, 2025 (GLOBE NEWSWIRE) -- Dear Shareholders, As envisioned, 2025 is unfolding to be an exciting year for CytoDyn Inc. (“CytoDyn” or the “Company”). On February 24, 2025, the Company [...]
CorMedix Inc. to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 25, 2025
18/03/2025
BERKELEY HEIGHTS, N.J., March 18, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and [...]
New InStride Health Data Reveals Overall Clinical Improvement in 98% of Youth with Anxiety and/or OCD
18/03/2025
Second Annual Outcomes Report confirms comprehensive, evidenced-based treatment program continues to prove clinically meaningful for graduates and families BOSTON, March 18, 2025 (GLOBE NEWSWIRE) -- InStride Health, an [...]
Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference
18/03/2025
HANOVER, Md., March 18, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation cancer [...]
Prenetics’ IM8 Health Expands Scientific Advisory Board, Reinforcing Commitment to Set New Standards in Supplements Market
18/03/2025
Adds Renowned Clinical Experts Dr. Jeremy London and Dr. Amy Shah to Existing Team from Mayo Clinic, Cedars-Sinai, NASA and Yale University CHARLOTTE, N.C., March 18, 2025 (GLOBE NEWSWIRE) -- IM8 , the premium [...]
Can-Fite: FDA Approved Compassionate Use Treatment with Namodenoson in a Pancreatic Cancer Patient
18/03/2025
Ramat Gan, Israel, March 18, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological [...]
Alvotech and Dr. Reddy’s Announce FDA acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®
18/03/2025
HYDERABAD, India and REYKJAVIK, Iceland, March 18, 2025 (GLOBE NEWSWIRE) -- Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries together referred to as “Dr [...]
AccuStem Sciences, Inc. Announces Acquisition of Proprietary MSC Lung Cancer Screening Test
18/03/2025
AccuStem pursuing strategic commercialization plan intending to launch the MSC test in the US in 2026 LONDON and PHOENIX, Ariz., March 18, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage [...]
Alvotech and Dr. Reddy’s Announce FDA acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®
18/03/2025
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries together referred to as “Dr. Reddy’s”) and Alvotech (NASDAQ: ALVO), a global biotech company [...]
Omega Laboratories Reports Completion of Method Validation with Cannabix Technologies Inc. for Marijuana Breath Detection
18/03/2025
VANCOUVER, British Columbia, March 18, 2025 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the “Company or Cannabix”) reports the following news release was issued by Omega [...]
Cytrellis Secures Health Canada and Saudi Food and Drug Authority Approval for ellacor® with Micro-Coring® Technology
18/03/2025
Authorizations are part of Growth Strategy to Expand Global Footprint WOBURN, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Cytrellis Biosystems, a medical technology company specializing in novel aesthetic solutions, today [...]
IN8bio to Participate at the 11th Annual Immuno-Oncology 360° Conference 2025
18/03/2025
NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc . (Nasdaq: INAB) , a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune diseases, today [...]
SCIENTURE announces the U.S. FDA Approval of its NDA for SCN-102, to be launched as ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL. The global market for losartan potassium was approximately $1.5 billion in sales in 2024.
18/03/2025
TAMPA, FL, March 18, 2025 (GLOBE NEWSWIRE) -- – SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, [...]
Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular Edema
18/03/2025
OCU200 has a very favorable safety and tolerability profile No serious adverse events related to the study drug have been reported Dosing of the second cohort has been approved MALVERN, Pa., March 18, 2025 (GLOBE [...]
Ashvattha Therapeutics Accelerates Clinical Development Strategy with Leadership Appointment of Six Leading Retinal Specialists to Clinical Advisory Board
18/03/2025
New Clinical Advisory Board brings together distinguished retinal specialists to provide strategic guidance on development of Ashvattha's innovative nanomedicine programs REDWOOD CITY, Calif., March 18, 2025 (GLOBE [...]
Candel Therapeutics Appoints Renowned Pancreatic Cancer Expert, Elizabeth M. Jaffee, M.D., to Research Advisory Board
18/03/2025
NEEDHAM, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies [...]
Italfarmaco and Medis Announce Exclusive Distribution Agreement for Givinostat in 17 Central and Eastern European Countries including the Baltic States
18/03/2025
Medis will have exclusive distribution rights in 17 EU and non-EU countries for givinostat once approved Regulatory approvals for givinostat as a treatment of Duchenne muscular dystrophy obtained in the US and UK; EMA [...]
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Major Depressive Disorder to take Place at Massachusetts General Hospital
18/03/2025
Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in MDD subjects ATLANTA, March 18, 2025 (GLOBE [...]

Pages